Attenuation of dark-induced hyperlocomotion by a cholecystokinin antagonist in the nucleus accumbens

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

A dark-induced hyperlocomotion paradigm was developed to investigate the role of endogenous cholecystokinin in mediating exploratory locomotor activity in the mesolimbic pathway, where cholecystokinin coexists with dopamine. Microinjection of the cholecystokinin receptor antagonist, proglumide, 10-20 μg, into the medial posterior nucleus accumbens, significantly inhibited dark-induced hyperlocomotion, while having no effect on locomotion in the light. These data suggest that endogenous cholecystokinin contributes to behaviorally relevant functions of the activated mesolimbic pathway.

Original languageEnglish (US)
Pages (from-to)398-400
Number of pages3
JournalBrain Research
Volume473
Issue number2
DOIs
StatePublished - Nov 15 1988
Externally publishedYes

Fingerprint

Cholecystokinin
Nucleus Accumbens
Locomotion
Proglumide
Cholecystokinin Receptors
Microinjections
Dopamine
Light

Keywords

  • Cholecystokinin
  • Coexistence
  • Dopamine
  • Endogenous
  • Locomotion
  • Neuropeptide

ASJC Scopus subject areas

  • Developmental Biology
  • Molecular Biology
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Attenuation of dark-induced hyperlocomotion by a cholecystokinin antagonist in the nucleus accumbens. / Crawley, Jacqueline.

In: Brain Research, Vol. 473, No. 2, 15.11.1988, p. 398-400.

Research output: Contribution to journalArticle

@article{1b5ee3e464804ef0a6b180bcb6c3bb4c,
title = "Attenuation of dark-induced hyperlocomotion by a cholecystokinin antagonist in the nucleus accumbens",
abstract = "A dark-induced hyperlocomotion paradigm was developed to investigate the role of endogenous cholecystokinin in mediating exploratory locomotor activity in the mesolimbic pathway, where cholecystokinin coexists with dopamine. Microinjection of the cholecystokinin receptor antagonist, proglumide, 10-20 μg, into the medial posterior nucleus accumbens, significantly inhibited dark-induced hyperlocomotion, while having no effect on locomotion in the light. These data suggest that endogenous cholecystokinin contributes to behaviorally relevant functions of the activated mesolimbic pathway.",
keywords = "Cholecystokinin, Coexistence, Dopamine, Endogenous, Locomotion, Neuropeptide",
author = "Jacqueline Crawley",
year = "1988",
month = "11",
day = "15",
doi = "10.1016/0006-8993(88)90874-8",
language = "English (US)",
volume = "473",
pages = "398--400",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Attenuation of dark-induced hyperlocomotion by a cholecystokinin antagonist in the nucleus accumbens

AU - Crawley, Jacqueline

PY - 1988/11/15

Y1 - 1988/11/15

N2 - A dark-induced hyperlocomotion paradigm was developed to investigate the role of endogenous cholecystokinin in mediating exploratory locomotor activity in the mesolimbic pathway, where cholecystokinin coexists with dopamine. Microinjection of the cholecystokinin receptor antagonist, proglumide, 10-20 μg, into the medial posterior nucleus accumbens, significantly inhibited dark-induced hyperlocomotion, while having no effect on locomotion in the light. These data suggest that endogenous cholecystokinin contributes to behaviorally relevant functions of the activated mesolimbic pathway.

AB - A dark-induced hyperlocomotion paradigm was developed to investigate the role of endogenous cholecystokinin in mediating exploratory locomotor activity in the mesolimbic pathway, where cholecystokinin coexists with dopamine. Microinjection of the cholecystokinin receptor antagonist, proglumide, 10-20 μg, into the medial posterior nucleus accumbens, significantly inhibited dark-induced hyperlocomotion, while having no effect on locomotion in the light. These data suggest that endogenous cholecystokinin contributes to behaviorally relevant functions of the activated mesolimbic pathway.

KW - Cholecystokinin

KW - Coexistence

KW - Dopamine

KW - Endogenous

KW - Locomotion

KW - Neuropeptide

UR - http://www.scopus.com/inward/record.url?scp=0024242575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024242575&partnerID=8YFLogxK

U2 - 10.1016/0006-8993(88)90874-8

DO - 10.1016/0006-8993(88)90874-8

M3 - Article

C2 - 3233498

AN - SCOPUS:0024242575

VL - 473

SP - 398

EP - 400

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 2

ER -